Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.

After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Novo Nordisk A/S’s next-generation obesity shot CagriSema helped patients lose weight in large studies despite only about ...

Presenting results from the REDEFINE 1 and REDEFINE 2 studies at the American Diabetes Association (ADA) congress in Chicago, ...

Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Shares in Novo Nordisk fell as much as 3.5% on Monday after ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults ...

Danish group lost €90bn in market capitalisation in December after preliminary results showed it missed its target ...

Novo Nordisk presented trial results from its trials evaluating the efficacy of CagriSema, another weight-loss drug. Patients ...

Omnicom's $13.5 billion acquisition of rival Interpublic can move forward on the condition the new company does not enter ...